Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
In a study of 12 adults with primary immunodeficiency and gastrointestinal distress, in-depth interviews were used to explore their experiences and the actions they take to relieve GI…
The phase 3 Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig (CARES10) study was designed to evaluate the safety, efficacy, and pharmacokinetics of a 10% intravenous immunoglobulin in…
In a study designed to investigate the biological relevance of PARP1 in multiple myeloma (MM), data revealed a significant correlation between increased PARP1 mRNA expression and poor prognosis…
In a study designed to analyze and improve the diagnostic sensitivity and specificity of the immunodeficiency disease-related scoring system in adult patients referred to immunology with clinical suspicion…
In an interview for NBC News, Vin Gupta, MD, MPA, MSc, affiliate assistant professor of Health Metrics Sciences at the Institute for Health Metrics and Evaluation (IHME) at…
Corey Cutler, MD, MPH, medical director of the Adult Stem Cell Transplantation Center at Dana-Farber Cancer Institute, discusses Blood and Marrow Clinical Trials Network Study 1102, comparing patients…
Phase 3 ASCERTAIN Trial Shows Promising Results with Oral Decitabine and Cedazuridine Combination for the Treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Naval Daver, MD, University of Texas MD Anderson Cancer Center, shares recent work on combination magrolimab, a CD47-targeting monoclonal antibody, and the hypomethylating agent azacitidine. The azacitidine and…
Dileep R. Yavagal, MD, FSVIN, interventional neurologist and chair of the leadership committee for MT2020+, a global initiative with the goal of accelerating worldwide access to rapid emergency…
